Show simple item record

dc.contributor.authorRalph, Stephen J
dc.contributor.authorWeissenberger, Andrew
dc.contributor.authorBonev, Ventzislav
dc.contributor.authorKing, Liam D
dc.contributor.authorBonham, Mikaela D
dc.contributor.authorFerguson, Samantha
dc.contributor.authorSmith, Ashley D
dc.contributor.authorGoodman-Jones, Adrienne A
dc.contributor.authorEspinet, Anthony J
dc.date.accessioned2020-05-25T03:35:00Z
dc.date.available2020-05-25T03:35:00Z
dc.date.issued2020
dc.identifier.issn1354-3784
dc.identifier.doi10.1080/13543784.2020.1709822
dc.identifier.urihttp://hdl.handle.net/10072/394047
dc.description.abstractBackground: Previous open-label studies showed that chronic post-stroke pain could be abated by treatment with perispinal etanercept, although these benefits were questioned. A randomized double-blind placebo controlled clinical trial was conducted to test perispinal etanercept for chronic post-stroke pain. Research design and methods: Participants received two treatments, either perispinal etanercept (active) or saline (control). Primary outcomes were the differences in daily pain levels between groups analyzed by SPSS. Results: On the 0–100 points visual analog scale, perispinal etanercept reduced mean levels for worst and average daily pain from baseline after two treatments by 19.5–24 points (p < 0.05), and pain alleviation was maintained in the etanercept group, with no significant change in the control group. Thirty percent of etanercept participants had near complete pain abatement after first treatment. Goniometry of the paretic arm showed improved mean shoulder rotation by 55 degrees in active forward flexion for the etanercept group (p = 0.003) only. Conclusions: Perispinal etanercept can provide significant and ongoing benefits for the chronic post-stroke management of pain and greater shoulder flexion by the paretic arm. Effects are rapid and highly significant, supporting direct action on brain function.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherTaylor & Francis Group
dc.relation.ispartofissue3
dc.relation.ispartofjournalExpert Opinion on Investigational Drugs
dc.relation.ispartofvolume29
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences
dc.subject.fieldofresearchOncology and carcinogenesis
dc.subject.fieldofresearchcode3214
dc.subject.fieldofresearchcode3211
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsPharmacology & Pharmacy
dc.subject.keywordsClinical trial
dc.subject.keywordsperispinal etanercept
dc.titlePhase I/II parallel double-blind randomized controlled clinical trial of perispinal etanercept for chronic stroke: improved mobility and pain alleviation
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationRalph, SJ; Weissenberger, A; Bonev, V; King, LD; Bonham, MD; Ferguson, S; Smith, AD; Goodman-Jones, AA; Espinet, AJ, Phase I/II parallel double-blind randomized controlled clinical trial of perispinal etanercept for chronic stroke: improved mobility and pain alleviation, Expert Opinion on Investigational Drugs, 2020, 29 (3)
dc.date.updated2020-05-20T00:38:26Z
dc.description.versionAccepted Manuscript (AM)
gro.rights.copyrightThis is an Author's Accepted Manuscript of an article published in Expert Opinion on Investigational Drugs, 2020, 29 (3), pp.311-326, 03 Jan 2020, copyright Taylor & Francis, available online at: https://doi.org/10.1080/13543784.2020.1709822
gro.hasfulltextFull Text
gro.griffith.authorRalph, Stephen J.
gro.griffith.authorFerguson, Samantha


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record